Altered triglyceride and phospholipid metabolism predates the diagnosis of gestational diabetes in obese pregnancy.
White, Sara L
Vieira, Matias C
MetadataShow full item record
Furse, S., White, S. L., Meek, C., Jenkins, B., Petry, C., Vieira, M. C., Ozanne, S., et al. (2019). Altered triglyceride and phospholipid metabolism predates the diagnosis of gestational diabetes in obese pregnancy.. Molecular omics, 15 (6), 420-430. https://doi.org/10.1039/c9mo00117d
A Gestational diabetes (GDM), a common pregnancy complication associated with obesity and long-term health risk, is usually diagnosed at approximately 28w of gestation. An understanding of lipid metabolism in women at risk of GDM could contribute to earlier diagnosis and treatment. We tested the hypothesis that altered lipid metabolism at the beginning of the second trimester in obese pregnant women is associated with a diagnosis of GDM. Plasma samples from 831 participants (16-45y, 15-18w gestation, BMI ≥30) from the UPBEAT study of obese pregnant women were used. The lipid, sterol and glyceride fraction was isolated and analysed in a semi-quantitative fashion using direct infusion mass spectrometry. A combination of uni-, multi-variate and multi-variable statistical analyses was used to identify candidate biomarkers in plasma associated with a diagnosis of GDM (early third trimester; IADPSG criteria). Multivariable adjusted analyses showed that participants who later developed GDM had a greater abundance of several triglycerides (48:0, 50:1, 50:2, 51:5, 53:4) and phosphatidylcholine (38:5). In contrast sphingomyelins (32:1, 41:2, 42:3), lyso-phosphatidylcholines (16:0, 18:1), phosphatidylcholines (35:2, 40:7, 40:10), two polyunsaturated triglycerides (46:5, 48:6) and several oxidised triglycerides (48:6, 54:4, 56:4, 58:6) were less abundant. We concluded that both lipid and triglyceride metabolism were altered at least 10 weeks before diagnosis of GDM. Further investigation is required to determine the functional consequences of these differences and the mechanisms by which they arise.
National Institute for Health Research ()
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Diabetes UK (17/0005712)
Biotechnology and Biological Sciences Research Council (BB/M027252/1)
External DOI: https://doi.org/10.1039/c9mo00117d
This record's URL: https://www.repository.cam.ac.uk/handle/1810/296754
All rights reserved